Published in Lancet on July 06, 2009
Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst (2013) 8.75
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
Correlates of protection induced by vaccination. Clin Vaccine Immunol (2010) 5.21
Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol (2015) 4.84
Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst (2011) 4.59
Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ (2009) 4.18
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst (2011) 3.92
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ (2011) 3.90
Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J Infect Dis (2011) 3.44
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Efficacy of a bivalent HPV 16/18 vaccine against anal HPV 16/18 infection among young women: a nested analysis within the Costa Rica Vaccine Trial. Lancet Oncol (2011) 2.85
Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst (2010) 2.81
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa Rica. Cancer Discov (2011) 2.66
Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis (2015) 2.48
The known unknowns of HPV natural history. J Clin Invest (2011) 2.39
Cancer immunotherapy--revisited. Nat Rev Drug Discov (2011) 2.26
Immunology and the elusive AIDS vaccine. Nature (2010) 2.26
In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe (2010) 2.24
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Human papillomavirus infection and increased risk of HIV acquisition. A systematic review and meta-analysis. AIDS (2012) 2.15
Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis (2010) 2.13
TLR-based immune adjuvants. Vaccine (2010) 2.10
HPV vaccine for all. Lancet (2009) 2.10
Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis (2010) 2.03
Evolutionary medicine: its scope, interest and potential. Proc Biol Sci (2012) 1.94
HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine (2011) 1.91
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol (2012) 1.78
Geographic poverty and racial/ethnic disparities in cervical cancer precursor rates in Connecticut, 2008-2009. Am J Public Health (2012) 1.76
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin (2011) 1.73
Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment. Am J Epidemiol (2013) 1.73
HPV vaccine decision making in pediatric primary care: a semi-structured interview study. BMC Pediatr (2011) 1.72
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin (2011) 1.65
Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med (2013) 1.64
Risk estimation for the next generation of prevention programmes for cervical cancer. Lancet Oncol (2009) 1.60
Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA. J Infect Dis (2014) 1.58
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Predicting human papillomavirus vaccine uptake in young adult women: comparing the health belief model and theory of planned behavior. Ann Behav Med (2012) 1.53
Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, Kenya. PLoS One (2014) 1.50
HPV - immune response to infection and vaccination. Infect Agent Cancer (2010) 1.48
Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother (2014) 1.48
A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer (2012) 1.47
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin (2011) 1.46
Preventing cervical cancer globally by acting locally: if not now, when? J Natl Cancer Inst (2010) 1.46
Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer (2014) 1.45
Direct benefit of vaccinating boys along with girls against oncogenic human papillomavirus: bayesian evidence synthesis. BMJ (2015) 1.43
Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010. Cancer (2012) 1.41
Multi-site study of HPV type-specific prevalence in women with cervical cancer, intraepithelial neoplasia and normal cytology, in England. Br J Cancer (2010) 1.41
Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Infect Dis (2012) 1.38
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Long-term follow-up in cancer prevention trials (It ain't over 'til it's over). Cancer Prev Res (Phila) (2010) 1.33
Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer (2014) 1.33
Epithelial cell responses to infection with human papillomavirus. Clin Microbiol Rev (2012) 1.33
A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol (2011) 1.32
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30
Epidemiology and clinical aspects of HPV in head and neck cancers. Head Neck Pathol (2012) 1.29
The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int (2014) 1.26
Human papillomavirus prevalence among indigenous and non-indigenous Australian women prior to a national HPV vaccination program. BMC Med (2011) 1.23
Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf (2014) 1.21
Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus vaccine. Saudi Med J (2014) 1.20
Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med (2011) 1.18
Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17
Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health (2012) 1.16
Mucosal vaccine adjuvants update. Clin Exp Vaccine Res (2012) 1.15
The paediatric story of human papillomavirus (Review). Oncol Lett (2014) 1.15
Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology (2015) 1.13
Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine (2013) 1.13
Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection. BMC Infect Dis (2012) 1.13
A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies. Clin Vaccine Immunol (2012) 1.13
Factors associated With Medicaid providers' recommendation of the HPV vaccine to low-income adolescent girls. J Adolesc Health (2013) 1.12
Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med (2011) 1.10
Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models. BMC Med (2011) 1.09
Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer (2010) 1.09
Prevalence of human papillomavirus genotypes and associated cervical squamous intraepithelial lesions in HIV-infected women in Botswana. J Med Virol (2011) 1.09
Human papillomavirus molecular biology and disease association. Rev Med Virol (2015) 1.09
Validation of a low-cost human papillomavirus genotyping assay based on PGMY PCR and reverse blotting hybridization with reusable membranes. J Clin Microbiol (2011) 1.09
Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine (2012) 1.08
Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine (2011) 1.07
Epidemiology of, and behavioural risk factors for, sexually transmitted human papillomavirus infection in men and women in Britain. Sex Transm Infect (2012) 1.07
Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus. Saudi Med J (2015) 1.06
Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine (2010) 1.05
Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One (2013) 1.04
Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04
A qualitative analysis of factors influencing HPV vaccine uptake in Soweto, South Africa among adolescents and their caregivers. PLoS One (2013) 1.04
Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review. Infect Agent Cancer (2011) 1.03
The prevention of infection-associated cancers. Carcinogenesis (2011) 1.03
HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med (2010) 1.03
Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J (2011) 1.02
Multiple human papillomavirus infections and type competition in men. J Infect Dis (2011) 1.02
Randomized controlled trials of interventions to prevent sexually transmitted infections: learning from the past to plan for the future. Epidemiol Rev (2010) 1.02
Human papillomavirus vaccine intent and uptake among female college students. J Am Coll Health (2012) 1.02
Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One (2010) 1.02
Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial. Vaccine (2014) 1.02
Evidence of immune memory 8.5 years following administration of a prophylactic human papillomavirus type 16 vaccine. J Clin Virol (2011) 1.01
Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin (2011) 1.01
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature (1997) 19.08
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol (1998) 9.43
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet (2008) 8.12
Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science (1998) 7.96
High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer (2006) 6.59
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med (1997) 6.23
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet (2009) 5.68
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
Chemokines and the arrest of lymphocytes rolling under flow conditions. Science (1998) 5.34
Human papillomavirus testing in primary cervical screening. Lancet (1995) 5.09
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis (1994) 4.89
Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med (1992) 4.81
Syphilis: review with emphasis on clinical, epidemiologic, and some biologic features. Clin Microbiol Rev (1999) 4.63
Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA (2001) 4.38
Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med (1986) 4.37
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int J Cancer (1992) 3.88
Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol (2001) 3.35
The structure of the hemagglutinin, a determinant for the pathogenicity of influenza viruses. Virology (1979) 3.25
Determinants of genital human papillomavirus detection in a US population. J Infect Dis (2001) 3.21
Subtelomere FISH analysis of 11 688 cases: an evaluation of the frequency and pattern of subtelomere rearrangements in individuals with developmental disabilities. J Med Genet (2005) 3.11
Mild cervical dyskaryosis: safety of cytological surveillance. Lancet (1992) 3.09
CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc Natl Acad Sci U S A (1999) 3.00
Liver biopsy: blind or guided? BMJ (1994) 2.86
Coronary heart disease in Western Collaborative Group Study. Final follow-up experience of 8 1/2 years. JAMA (1975) 2.84
Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia (2000) 2.84
Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc (1988) 2.82
A study of treatment failures following large loop excision of the transformation zone for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol (1997) 2.71
Molecular investigation of a multisource outbreak of Crimean-Congo hemorrhagic fever in the United Arab Emirates. Am J Trop Med Hyg (1997) 2.66
Immunogenicity and acceptability of a human diploid-cell culture rabies vaccine in volunteers. Lancet (1975) 2.61
Comparison of ViraPap, Southern hybridization, and polymerase chain reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer. J Clin Microbiol (1992) 2.60
Identification of polyphosphate-accumulating organisms and design of 16S rRNA-directed probes for their detection and quantitation. Appl Environ Microbiol (2000) 2.57
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol (1995) 2.46
Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate. Pediatr Infect Dis J (1995) 2.44
Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol (2007) 2.40
Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol (1997) 2.40
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Prevalence of human papillomavirus type 16 DNA sequences in cervical intraepithelial neoplasia and invasive carcinoma of the cervix. Br J Obstet Gynaecol (1985) 2.28
Persisting mortality in diabetic ketoacidosis. Diabet Med (1993) 2.28
Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer (1994) 2.23
Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer (2001) 2.22
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst (1998) 2.19
Proteolytic activation of the influenza virus hemagglutinin: The structure of the cleavage site and the enzymes involved in cleavage. Virology (1981) 2.13
Early loss of heterozygosity on 17q in ovarian cancer. The Abe Ovarian Cancer Genetics Group. Oncogene (1992) 2.13
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
THE ROLE OF THE BURROWING OWL AND THE STICKTIGHT FLEA IN THE SPREAD OF PLAGUE. Science (1941) 2.12
Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol (2001) 2.08
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 2.06
Genetic diversity and HIV detection by polymerase chain reaction. Lancet (1995) 2.03
Withdrawing low risk women from cervical screening programmes: mathematical modelling study. BMJ (1999) 2.03
A second-generation study of 427 probands with congenital heart defects and their 837 children. J Am Coll Cardiol (1994) 1.97
Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine (2010) 1.94
Rescue of the albino phenotype by introduction of a functional tyrosinase gene into mice. EMBO J (1990) 1.91
Risk factors for rapid-onset cervical cancer. Am J Obstet Gynecol (1999) 1.91
Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol (1999) 1.90
Crimean-Congo haemorrhagic fever in Oman. Lancet (1995) 1.90
High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis (2009) 1.89
Suppressors of superoxide dismutase (SOD1) deficiency in Saccharomyces cerevisiae. Identification of proteins predicted to mediate iron-sulfur cluster assembly. J Biol Chem (1998) 1.88
Comparison of performances of two commercially available tests, a PCR assay and a ligase chain reaction test, in detection of urogenital Chlamydia trachomatis infection. J Clin Microbiol (1998) 1.85
Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res (2001) 1.85
Prevalence and determinants of human papillomavirus genital infection in men. Br J Cancer (2002) 1.83
Chlamydial endometritis. J Clin Pathol (1985) 1.80
International trends in incidence of cervical cancer: II. Squamous-cell carcinoma. Int J Cancer (2000) 1.79
Early menarche, a risk factor for breast cancer, indicates early onset of ovulatory cycles. J Clin Endocrinol Metab (1983) 1.79
Changes in cross-sectional measurements of the spinal canal and intervertebral foramina as a function of body position: in vivo studies on an open-configuration MR system. AJR Am J Roentgenol (1999) 1.79
Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol (2009) 1.77
Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem (1995) 1.75
Multicenter comparison of three commercial methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1996) 1.75
Current views on cervical intraepithelial neoplasia. J Clin Pathol (1991) 1.72
Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect (2003) 1.70
Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecol Oncol (2012) 1.70
3-Aminopropyltriethoxysilane (APES): a new advance in section adhesion. J Clin Pathol (1987) 1.70
Histological and immunocytochemical study of cervical intraepithelial neoplasia (CIN) with associated HPV 6 and HPV 16 infections. J Clin Pathol (1986) 1.70
The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer (1998) 1.69
Human papillomavirus genotypes in rural Mozambique. Lancet (2001) 1.69
Chlamydia trachomatis seroprevalence atlas of Finland 1983-2003. Sex Transm Infect (2007) 1.69
Social adjustment after rehabilitation: a two year follow-up of patients with severe head injury. Psychol Med (1980) 1.68
Human papillomavirus: a highly prevalent sexually transmitted disease agent among female sex workers from Mexico City. Sex Transm Dis (2001) 1.68
Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer (2013) 1.68